Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis

The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna’s KYSA-7 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., Jan. 19, 2024…

Click here to view original post